Open Access Highly Accessed Research article

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

Takayoshi Kiba1*, Takuo Ito2, Toshihisa Nakashima3, Yoshiko Okikawa2, Miki Kido2, Akiko Kimura2, Keita Kameda3, Fumiaki Miyamae3, Suzuko Tanaka4, Misao Atsumi4, Yoko Sumitani4, Yoshimi Shitakubo1 and Hiromasa Niimi2

Author Affiliations

1 Division of Modern Medical Technology, Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, 3-1, Aoyama-cho, Kure-shi, Hiroshima 737-0023, Japan

2 Department of Hematology and Oncology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, 3-1, Aoyama-cho, Kure-shi, Hiroshima 737-0023, Japan

3 Department of Pharmacy, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, 3-1, Aoyama-cho, Kure-shi, Hiroshima 737-0023, Japan

4 Clinical Trial Management Office, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, 3-1, Aoyama-cho, Kure-shi, Hiroshima 737-0023, Japan

For all author emails, please log on.

BMC Cancer 2014, 14:462  doi:10.1186/1471-2407-14-462

Published: 21 June 2014

Abstract

Background

Bortezomib offers a novel approach to the treatment of multiple myeloma producing rapid control. The aim of this study was to investigate the outcomes of bortezomib and dexamethasone-treated patients with multiple myeloma.

Methods

We conducted a retrospective study of 44 consecutively-treated multiple myeloma patients with bortezomib (1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle or 1.3 mg/m2 intravenously 1, 8, 15, and 22 of every 35-day cycle) and dexamethasone.

Results

The median time to progression, progression free survival time, and overall survival time in the treatment groups was 14.9, 14.9, and 38.3 months, respectively. The present study also suggests the possibility that the prognosis of patients with high levels of AST and LDH might be worse.

Conclusions

Our results indicate that the treatment of multiple myeloma with bortezomib and dexamethasone is feasible.

Keywords:
Bortezomib; Multiple myeloma; Prognosis